PHVS Phase 3 CHAPTER-3: deucrictibant XR cuts HAE attacks 83%
PHVS says its Phase 3 CHAPTER-3 trial showed deucrictibant XR 40 mg once daily reduced hereditary angioedema attack rates by 83% versus placebo, with rapid onset, sustained effect, improved quality of life, and a favorable safety profile.